SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is experiencing a parabolic surge, fueled by escalating industrial demand for silver in new technologies and anticipation of China's upcoming export restrictions. Community discussion highlights a potential short squeeze and belief that long-term price suppression is ending, though some anticipate a sharp correction after such an aggressive run.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending with gold prices reaching new all-time highs, driven by escalating geopolitical tensions, a weakening dollar, and widespread anticipation of significant Fed monetary easing. The community is actively debating whether this surge reflects a "currency reset" and a flight to real assets amid an over-indebted global environment, or if it signals an overheated market due for a correction, with many noting a rotation of investment capital from cryptocurrencies into precious metals.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending due to its real-world asset integration via Cocky Wings LLC, which is actively generating revenue and performing token buybacks, enhancing liquidity. The community on Cardano is highly engaged, discussing its new DApp, passive earning opportunities in the 'Arena,' and its long-term potential as a utility-backed meme coin.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

ASPC is experiencing extreme price volatility and massive trading volume, sparking widespread community discussion around a potential short squeeze. Traders are actively debating its rapid movements, with some anticipating significant further momentum while others caution about the inherent risks of such speculative, low-float plays. The overall sentiment is sharply divided between those betting on continued upside and those warning of a pump-and-dump dynamic.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG CRYPTO is trending due to significant community discussion around its unique position as a Bitcoin-native memecoin, particularly on the Runes protocol. Bulls are highlighting recent strategic acquisitions by C2 Blockchain, which has notably expanded its $DOG treasury. The "DOG Army" expresses strong conviction, positioning $DOG as a contender to "drop the E" and become a dominant meme asset on the secure Bitcoin network.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Sprott Physical Silver Trust (PSLV) is experiencing significant attention as the community widely discusses a powerful silver squeeze, driven by a growing structural supply deficit and surging industrial demand across critical sectors. Many believe long-standing market suppression is breaking, potentially leading to a historic price discovery phase. Investor conversations emphasize the intrinsic value of physical silver as a hedge against broader economic uncertainties.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Trust - ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is currently trending amidst widespread community belief in a historic silver breakout, driven by strong industrial demand, geopolitical instability, and anticipation of central bank dovish pivots. Investors are actively discussing extreme upside targets for silver and its leveraged ETFs, with many highlighting its undervalued status relative to gold and expressing a "silver squeeze" narrative.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the landmark FDA approval of YARTEMLEA, establishing it as the first and only approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA) in both adult and pediatric patients. This pivotal de-risking event, coupled with its strengthened financial position from a major partnership, has fueled community excitement regarding commercialization potential, anticipated analyst upgrades, and significant upside ahead of its upcoming conference call.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals (UPC) is trending due to a massive surge in trading volume and significant price volatility, driven by its extremely low public float. Community sentiment is highly polarized, with some anticipating a substantial short squeeze and advocating for holding shares for significant gains, while others caution it's a 'pump and dump' given its status as a China-based micro-cap. Discussion often highlights the company's strong cash position relative to its market capitalization, fueling speculation of high intrinsic value and potential for rapid upward movement if buying pressure continues.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending amid significant trading volume, driven by renewed investor interest in its compute-in-memory (CIM) APU technology following sector developments. The community is actively debating the company's potential as a disruptive force in edge AI, with discussions centering on its low-power Gemini chips for defense, drone, and satellite applications, including partnerships. Anticipation for upcoming multi-modal large language model benchmarks is also fueling conversation around GSIT's unique position in the evolving AI hardware landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC

Acorn Capital Advisors LLC lowered its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 97.9% in the second quarter, according to the company in its most recent filing with...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have been given an average rating of "Hold" by the five ratings firms that are presently covering the stock, Marketbeat.com reports...

X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Zacks Research

Zacks Research lowered shares of X4 Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday...

Wall Street Zen Upgrades X4 Pharmaceuticals (NASDAQ:XFOR) to "Hold"

Wall Street Zen raised shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...

MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +12.66% and -7.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Meets Q1 Earnings Estimates

Techne (TECH) delivered earnings and revenue surprises of 0.00% and -0.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

X4 Pharmaceuticals (XFOR) announced on Wednesday that it will reduce its workforce by 50% as part of a strategic restructuring.The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-restructuring-business-operations">said.</a> The strategic restructuring is aimed at aligning resources to complete the late-stage trial of Mavorixafor in patients with moderate and severe chronic neutropenia, it added.Shares of the company traded 0.5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/XFOR">XFOR stock</a> rose from 'bearish' to 'neutral' territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.The Boston-headquartered firm announced that Chief Legal and Compliance Officer Natasha Thoren, Chief Operating Officer Mary DiBiase, and Chief Commercial Officer Mark Baldry will be exiting the company as part of the workforce reduction. Chief Medical Officer Christophe Arbet‑Engels, meanwhile, is resigning for personal reasons, it added.“Over the coming weeks, we plan to continue to drive operational efficiencies, consolidate resources, and strengthen our leadership structure. With these changes, we expect to be well-positioned to become a world‑class hematology company, beginning with the advancement of mavorixafor into chronic neutropenia,” said Executive Chairman Adam Craig.The company also appointed its President, John Volpone, as the COO, and he will now oversee day‑to‑day operational management and business execution in his expanded role. Craig, meanwhile, will oversee clinical development.The company’s Mavorixafor is marketed as Xolremdi in the U.S. for the treatment of people aged 12 years and older with WHIM syndrome — a rare, primary immunodeficiency disorder that impairs white blood cell movement from the bone marrow to the bloodstream. The company is now evaluating additional uses of Mavorixafor and is conducting a global, pivotal late-stage clinical trial in people with certain chronic neutropenic disorders. Neutropenia is characterized by an abnormally low number of neutrophils, a type of white blood cell essential for fighting bacterial and fungal infections.XFOR stock is down by about 85% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-says-asthma-drug-failed-trial-in-smokers-disease/chDGnwkRd64">AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial

The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.

Equity

The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.


X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The firm is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.26	--	--	N/A
Q3 '25	-$0.50	-$0.69	-36.63%	MISSED
Q2 '25	-$3.37	--	--	N/A
Q1 '25	-$3.55	$0.04	101.13%	BEAT
Q4 '24	-$0.17	-$6.00	-3328.57%	MISSED

XFOR
X4 Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest XFOR News

XFORX4 Pharmaceuticals Inc